The overall objective is to include human prostatic cancer cell lines for discovering cancer chemotherapeutic drugs. Specific aims of Phase I include establishment and characterization of new human prostatic cancer cell strains/lines suitable for drug evaluation. These studies will include the use of special culture media and experimental conditions required for the establishment of fastidious, yet urgently needed, prostatic cancer cell lines. With data obtained from a panel of new cell strains/lines developed from individual patients during Phase I, drug sensitivity data from currently available prostatic cancer lines will be compared in Phase II. The main technical innovation will be the application of new strategies for the isolation and culture of prostatic cancer cells. All products and procedures developed during Phase I will be further refined in Phase II that would enable the discovery of new drugs against prostatic cancer.Awardee's statement of the potential commercial applications of the research:An obvious commercial application is to use the new human prostatic cancer cell lines for screening anticancer drugs. Spinoffs include the sale of culture media specially formulated for the establishment and maintenance of human prostatic cancer cell culture to laboratories engaged in prostatic cancer studies.National Cancer Institute (NCI)
